Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complication Clear all
Terminated Phase 2 Interventional Results available

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

NCT01663285
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Neoadjuvant Cisplatin and Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Phase II ABT-888 With Cyclophosphamide

NCT01306032
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Davis, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 6, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

NCT05845021
View directory record Official record
Conditions
Osteoporosis, Arthroplasty Complications, Fragility Fracture
Interventions
Surgeon-Initiated Bone Health Referral Pathway
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Exposure to Stress, Postpartum Mood, Adverse Life Events, and Hormonal Function Among Latinas (SEPAH Latina)

NCT01912833
View directory record Official record
Conditions
Postpartum Depression
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833
View directory record Official record
Conditions
Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
Interventions
Nintedanib, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 6, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT00714948
View directory record Official record
Conditions
Bladder Cancer, URINARY BLADDER
Interventions
gemcitabine and cisplatin plus sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers

NCT01088555
View directory record Official record
Conditions
Kidney Stones
Interventions
Sodium thiosulfate
Drug
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 6, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

NCT05144971
View directory record Official record
Conditions
Diabete Mellitus, CKD, ESRD
Interventions
Glucose, Creatinine
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Laparoscopic Approach to Cervical Cancer

NCT00614211
View directory record Official record
Conditions
Cervical Cancer
Interventions
Total Abdominal Radical Hysterectomy, Total Laparoscopic or Robotic Radical Hysterectomy
Procedure
Lead sponsor
Queensland Centre for Gynaecological Cancer
Government
Eligibility
18 Years and older · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
6
States / cities
Baltimore, Maryland • Las Vegas, Nevada • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 6, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
zigakibart
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Denver, Colorado • Acworth, Georgia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 6, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Intraoperative Methadone for Postoperative Pain Control After Thoracic Surgery

NCT04525898
View directory record Official record
Conditions
Postoperative Pain
Interventions
Methadone
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 6, 2026, 6:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Dato-DXd, Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
38
States / cities
Fullerton, California • Glendale, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Not applicable Interventional

A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)

NCT00196521
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Tension-free vaginal tape obturator system
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Denver, Colorado • Norwalk, Connecticut • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Sep 6, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Multifactorial Approach to Emergent Cerclage

NCT01114516
View directory record Official record
Conditions
Cervical Insufficiency
Interventions
Indomethacin and antibiotics (cefazolin or clindamycin)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 6, 2026, 6:50 AM EDT
Completed No phase listed Observational

Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart

NCT01622816
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Julia Haller
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Sep 6, 2026, 6:50 AM EDT
Withdrawn No phase listed Observational

Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)

NCT00250016
View directory record Official record
Conditions
Corpus Uteri, Endometrial Cancer
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 6, 2026, 6:50 AM EDT
Withdrawn Phase 4 Interventional

Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis

NCT01721616
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin, Cefazolin
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 6, 2026, 6:50 AM EDT
Terminated No phase listed Observational

NXT Post-Market Clinical Follow-up

NCT06336304
View directory record Official record
Conditions
Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Incontinence, Urge
Interventions
Urodynamic procedure
Diagnostic Test
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Hanover, Maryland • Owing Mills, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia

NCT03735433
View directory record Official record
Conditions
Preeclampsia
Interventions
162mg aspirin dose
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 6, 2026, 6:50 AM EDT
Withdrawn Phase 2 Interventional

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

NCT01893658
View directory record Official record
Conditions
Acute Interstitial Nephritis
Interventions
Omalizumab, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 6, 2026, 6:50 AM EDT
Active, not recruiting Not applicable Interventional

Split Chest Breast Neurotization

NCT05757778
View directory record Official record
Conditions
Breast Implant; Complications
Interventions
Sensory Nerve Coaptation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 6, 2026, 6:50 AM EDT
Completed No phase listed Observational

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

NCT03043287
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Shreveport, Louisiana • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 6, 2026, 6:50 AM EDT